PDCD1 and non-small cell lung carcinoma: The aim of this study is to explore the predictive value of 18F-FDG PET metabolic parameters, including PET metabolic parameters of primary lesions and systemic lesions, in the survival prognosis of advanced NSCLC patients treated with PD-1/PD-L1 inhibitors with/without chemotherapy.